Why sixteen and not fifteen?

Because the group with no components is the control, and without it none of the other fifteen means anything. Two to the fourth power counts it, which is correct.

Do regulators require this for combination medicines?

For fixed-dose combinations of licensed drugs, evidence that each component contributes to the claimed effect is generally expected, and factorial designs are the usual way to supply it. None of the components here is a licensed drug and no such requirement has been engaged.

Could a cell assay do this more cheaply than an animal study?

Yes, and that is where such a design would sensibly start - sixteen conditions in a plate is routine. The constraint is not the assay but the unstated composition, which makes the single-component arms unreconstructable from the product itself.

Is the absence of studies suspicious?

It is expected. Combination studies of unlicensed research compounds are rarely funded by anyone, and the design cost above is substantial. The absence is a reason not to make combination claims, not evidence that the components are inert.

KLOW (Blend)

Sixteen Arms Before You Have Asked a Single Question

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-244 cited sources

Establishing what a four-component combination contributes requires comparing it against every subset of its own components. For four components that is sixteen groups at a single dose level, before any dose-response range, replication or control for timing is added to the design.

Key facts

Components: 4
Subsets of four components: 16, including the empty set
Groups in a full factorial: 16 at one dose level
At three dose levels per component: 81 combinations of level
Minimum to claim synergy: Each component alone plus the combination
Published studies on this combination: None
Published studies on the three-component blend: None
Why the arithmetic matters: It explains the absence rather than excusing it

The question a blend invites and cannot answer

Putting four compounds in one vial invites the inference that the four do something together. Testing that inference is a specific experimental problem with a known solution and a known cost, and setting out the cost explains why the work does not exist. It is not that nobody has thought of it. It is that the design required is large, and it must be run on a product whose composition is not disclosed.

The factorial arithmetic

A factorial design tests every combination of present and absent for each factor. With four components each either in or out, the number of groups is two to the fourth power: sixteen. That includes the vehicle group with nothing in it, the four single-component groups, the six pairs, the four triples and the full combination. Sixteen groups is the minimum at a single fixed dose level, and it is the minimum that allows any statement of the form 'the fourth component adds something the other three do not provide'. Anything less leaves at least one comparison unmade and at least one attribution unsupported.

Research material referenced

KLOW 80mg — third-party HPLC tested

View — £69.99

And that is the cheap version

Sixteen assumes one concentration per component, which almost never suffices, because a component present at too low a level looks inactive and one present at too high a level can mask the others. Three levels per component - low, mid, high - gives three to the fourth power, or eighty-one combinations, before replication. Add the timing problem, since components with different persistence make the measurement time a hidden variable, and the design grows again. This is why combination pharmacology in practice usually tests two components rather than four, and why regulators reviewing fixed-dose combinations of licensed drugs generally require the factorial evidence only for the components actually claimed to contribute.

The problem specific to a fixed-ratio product

Even a well-funded group could not run this design using the blend alone. The single-component and subset arms require each component separately, at the concentration it occupies within the blend - and that concentration is not stated. So the experiment must be reconstructed from separately sourced components at assumed proportions, at which point it is no longer a study of the product but a study of the investigator's reconstruction of it. That gap between the product and the studiable object is the structural reason a blend can invite a combination claim it can never support.

What a smaller, honest study could establish

Not synergy, but something. A one-factor comparison - the four-component blend against the three-component blend that differs from it by exactly one component - is available off the shelf, since the two products exist and differ in a single defined way. That comparison cannot say what any individual component does, and it cannot distinguish addition from interaction. It can say whether the two products behave differently in a given system, which is a real if narrow finding and considerably more than any published work currently offers.

The honest position

No published work addresses this combination. That is a statement about absence of evidence, not evidence of absence, and it should not be read either as scepticism about the components or as reassurance about the mixture. The components have separate literatures of varying size and quality, each belonging to the compound and the model that generated it. Adding four literatures together does not produce a fifth about the vial. All four components are supplied for laboratory research only and none holds a marketing authorisation from the MHRA, EMA or FDA.

Quick reference

Design	Groups required	What it can establish
Blend vs vehicle	2	That the blend does something
Blend vs three-component blend	2	That one component changes the result
Each component alone plus blend	6	Whether the blend exceeds the parts
Full factorial, one dose level	16	The contribution of every subset
Full factorial, three dose levels	81	Contribution across a dose range

Extended research context

The KLOW (Blend) deep dive

Deep dive: a fourfold size range in one cake, and what partial dissolution hides

KLOW's components run from KPV at 342.43 daltons to BPC-157 at 1419.5 - a fourfold span, and the widest of any product in this catalogue. Solubility depends on size, charge distribution and hydrophobicity, and these four differ in all three, so a co-lyophilised cake containing all of them releases its components in sequence rather than together. The hazard follows directly and is easy to miss: a cake that looks partly dissolved is not uniformly partly dissolved. The smallest component may be entirely in solution while the largest has barely started. Draw from the vial at that moment and the sample is enriched in the fast components and depleted in the slow ones - a composition error with no visible sign at all, since the liquid looks like liquid. The instinctive response to visible solid makes it worse: shaking creates air-liquid interfaces, which is exactly where peptides unfold and then aggregate irreversibly. The correct response is diluent down the vial wall, gentle swirling, and more patience than a single peptide or even a three-component blend requires. There is a second asymmetry on top. Small peptides adsorb to glass and plastic more readily than large ones, so KPV is the component most likely to be lost to container walls at low concentration - a silent shift in the effective ratio that no certificate figure accounts for.

Deep dive: the cleanest possible comparison, which still cannot be run

KLOW is a strict superset of GLOW - the same three components plus KPV, at 80 mg against 70 mg. Product comparisons rarely have this structure. There is nothing in GLOW that KLOW lacks, so the difference between them reduces to a single question rather than a balance of trade-offs, and in principle comparing the two would isolate exactly what KPV contributes. In practice it cannot be done. The 10 mg difference in total might be 10 mg of added KPV with the other three unchanged, or it might be a redistribution across all four; both are consistent with the published figures, and neither product states its split. So any difference observed between the two could be KPV, or it could be a changed concentration of GHK-Cu, BPC-157 or TB-500. The experiment that the product pairing seems designed to permit is precisely the one the missing information forbids. This is the fixed-ratio limitation in its sharpest form: not that the format is unhelpful in general, but that it withholds the one number that would make the most natural question answerable.

Deep dive: two products from one hormone, in categories that never mention each other

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, isolated because that hormone does two functionally separable things - pigmentation through melanocortin receptors, and anti-inflammatory activity localised to its C-terminal end. KPV keeps the second and discards the first. Now look elsewhere in this catalogue: MT-2 is also an alpha-MSH derivative, and it is built around the melanocortin-receptor-binding core that KPV was specifically designed to leave behind. Two products, one parent hormone, opposite halves of its function, sitting in entirely separate product categories with nothing in either listing to indicate they are related. The size difference tracks the design logic. KPV at 342.43 daltons is three residues with no modifications, because an effect running through diffuse intracellular signalling can survive extreme truncation. MT-2 at 1024.2 daltons is seven residues plus a lactam bridge, a D-amino acid and two capped termini, because receptor engagement requires enough structure to present a specific surface. What a fragment needs to be depends entirely on what the retained function requires, and these two are as clean an illustration of that as this catalogue contains.

Research applications

▸Multi-component connective tissue research protocols
▸Comparative work on three-component versus four-component combinations
▸Co-lyophilisation and multi-component dissolution methodology
▸Copper peptide compatibility studies
▸Surface adsorption behaviour across a wide molecular size range
▸Anti-inflammatory and matrix pathway research

Handling checklist

✓Verify KPV as Lys-Pro-Val at 342.43 Da, CID 125672 - never by searching 'KPV'
✓Verify GHK-Cu against 402.92 Da (CID 71587328), not 340.38 for free GHK
✓Verify TB-500 against 889.0 Da, not 4.9 kDa for thymosin beta-4
✓Verify BPC-157 against 1419.5 Da
✓Expect four separate certifications - a single combined purity figure is a category error
✓Allow more dissolution time than a three-component blend; do not draw before it completes
✓Use low-binding consumables - KPV is the component most lost to surfaces
✓Store lyophilised, cold, dry and dark; the copper complex governs light protection

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Drawing from a partly dissolved four-component cake

Fix: Components dissolve in sequence across a fourfold size range. An early sample is enriched in fast components and depleted in slow ones, with no visible sign.

✗ Verifying the KPV component by searching 'KPV' in PubChem

Fix: That returns 2-oxo-5-phenylpentanoic acid at 192.21 Da, an unrelated compound. Search Lys-Pro-Val for CID 125672.

✗ Assuming the 10mg difference from GLOW is 10mg of KPV

Fix: Not stated. It could be added KPV with the others unchanged, or a redistribution across all four.

✗ Treating four component literatures as evidence about the blend

Fix: No published work addresses this combination or any subset of it. Summing separate literatures produces no evidence about a mixture.

✗ Adding a chelator because the blend contains copper

Fix: Unnecessary. None of the four components contains cysteine or methionine, so copper-catalysed oxidation has no substrate here.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Why sixteen and not fifteen?: Because the group with no components is the control, and without it none of the other fifteen means anything. Two to the fourth power counts it, which is correct.
Do regulators require this for combination medicines?: For fixed-dose combinations of licensed drugs, evidence that each component contributes to the claimed effect is generally expected, and factorial designs are the usual way to supply it. None of the components here is a licensed drug and no such requirement has been engaged.
Could a cell assay do this more cheaply than an animal study?: Yes, and that is where such a design would sensibly start - sixteen conditions in a plate is routine. The constraint is not the assay but the unstated composition, which makes the single-component arms unreconstructable from the product itself.
Is the absence of studies suspicious?: It is expected. Combination studies of unlicensed research compounds are rarely funded by anyone, and the design cost above is substantial. The absence is a reason not to make combination claims, not evidence that the components are inert.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More KLOW (Blend) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum